GlassScriptPhysician profile
Michael Axline
NPI 1740845072
$2,293.69
in general payments reported to CMS, 2019-2025
11 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $394 · 2024: $859 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Travel and Lodging: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.87 |
| Travel and Lodging | $310.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,194.02 | 2023-2025 | Impella |
| Medtronic, INC. | $361.82 | 2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $209.24 | 2023-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.71 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $119.50 | 2024-2025 | Wainua |
| Esperion Therapeutics, INC. | $65.34 | 2024-2025 | Nexletol |
| Pfizer INC. | $49.56 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $49.46 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $44.49 | 2025 | Attruby |
| Cvrx, INC. | $43.94 | 2025 | Barostim Neo System |
| Philips North America LLC | $32.61 | 2025 | Intracardiac Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Axline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.